Patent application number | Description | Published |
20100109876 | Devices, Systems and Methods to Control Caloric Intake - Devices, systems and methods are disclosed which relate to training a user in controlling and limiting total calorie consumption, and consequently body weight, by encouraging the user to perform specified consuming actions such as chewing slowly, adjusting a time interval between bites, detecting the early points of satiation, etc. The disclosure is therefore a “calorie pacer” that naturally reduces calorie consumption by re-teaching a user how to eat on a step-by-step basis. The slower eating pace results in a person feeling full before the intake of excessive food portions. The result is fewer calories consumed. Sensors and microcontrollers throughout a place setting are utilized to prompt the user, for example, when to take bites, how big of a bite to take, when to take a drink, etc and record the data in an efficient manner that allows for analysis, monitoring of progress, and personalized feedback. | 05-06-2010 |
20100179091 | Treatment of Conditions Related to Shock - Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent or combination of therapeutic agents, which is/are able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques. | 07-15-2010 |
20100303799 | Treatment of Conditions Related to Shock - Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques. | 12-02-2010 |
20110039781 | Treatment of Conditions Related to Cecal Ligation Shock - Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination of enzyme inhibitor, cytotoxic lipid binding protein, and antibiotic. | 02-17-2011 |
20120196935 | METHODS FOR DETECTING AUTODIGESTION - Materials and methods for detecting the early onset of shock and multi-organ failure by production of tissue breakdown products in biological samples (e.g., expired air). | 08-02-2012 |
20120309693 | Methods to Accelerate Tissue and Wound Healing Rates and Reduce Swelling and Scar Formation - The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor. | 12-06-2012 |
20130158394 | Devices, Systems and Methods to Detect and Reduce or Prevent Entry of Inflammatory Mediators into Milk Ducts - Devices, systems and methods are disclosed for measurement and reduction or prevention of fluid movement in lactiferous ducts, detection of diseased conditions in the breasts, and treatments thereof. Such techniques, methods and devices are applicable to a variety of conditions including carcinomas. | 06-20-2013 |
20130231309 | TREATMENT OF INFLAMMATION AND ORGAN DYSFUNCTION - Compositions and methods are disclosed for decreasing the amount and activity of matrix-degrading metalloproteinases (MMPs) in and around cells. The compositions and methods are useful for treating and/or preventing symptoms of diseases including but not limited to Hypertension, Type II Diabetes, and Metabolic Syndrome X. Such treatment is effected by normalizing the blood plasma's protease activity, reducing blood pressure, preventing membrane receptor cleavage, and reducing the levels of insulin resistance and oxygen free radicals in the blood stream. | 09-05-2013 |
20130310325 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH - The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum. | 11-21-2013 |
20140018293 | MINIMIZING INTESTINAL DYSFUNCTION - Techniques are discloded for treating or reducing sumptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator. | 01-16-2014 |